Literature DB >> 15547168

Left ventricular hypertrophy: the next treatable, silent killer?

Julius M Gardin, Michael S Lauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15547168     DOI： 10.1001/jama.292.19.2396

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  35 in total

1.  Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation.

Authors:  Petri Sipola; Jarkko Magga; Minna Husso; Pertti Jääskeläinen; Keijo Peuhkurinen; Johanna Kuusisto
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

2.  HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.

Authors:  Tianjing Hu; Friederike C Schreiter; Rushita A Bagchi; Philip D Tatman; Mark Hannink; Timothy A McKinsey
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

Review 3.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.

Authors:  Timothy A McKinsey; Eric N Olson
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  Effect of catheter ablation on the left ventricular mass index and other echocardiograph parameters in atrial fibrillation patients: comparison with antiarrhythmic drug treatment.

Authors:  Ki-Hun Kim; Jin Oh Na; Gi-Byoung Nam; Eun-Sun Jin; HyungOh Choi; Sung-Hwan Kim; Kee-Joon Choi; You-Ho Kim
Journal:  J Echocardiogr       Date:  2010-10-05

5.  Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial.

Authors:  Lorraine Levitt Katz; Samuel S Gidding; Fida Bacha; Kathryn Hirst; Siripoom McKay; Laura Pyle; Joao A C Lima
Journal:  Pediatr Diabetes       Date:  2014-01-22       Impact factor: 4.866

6.  Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy.

Authors:  Dao-Fu Dai; Tony Chen; Hazel Szeto; Madeline Nieves-Cintrón; Vassily Kutyavin; Luis F Santana; Peter S Rabinovitch
Journal:  J Am Coll Cardiol       Date:  2011-05-27       Impact factor: 24.094

7.  Regulation of cardiac stress signaling by protein kinase d1.

Authors:  Brooke C Harrison; Mi-Sung Kim; Eva van Rooij; Craig F Plato; Philip J Papst; Rick B Vega; John A McAnally; James A Richardson; Rhonda Bassel-Duby; Eric N Olson; Timothy A McKinsey
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

8.  Nuclear translocation of calmodulin in pathological cardiac hypertrophy originates from ryanodine receptor bound calmodulin.

Authors:  Tetsuro Oda; Takeshi Yamamoto; Takayoshi Kato; Hitoshi Uchinoumi; Go Fukui; Yoriomi Hamada; Takuma Nanno; Hironori Ishiguchi; Yoshihide Nakamura; Yoko Okamoto; Michiaki Kono; Shinichi Okuda; Shigeki Kobayashi; Donald M Bers; Masafumi Yano
Journal:  J Mol Cell Cardiol       Date:  2018-10-22       Impact factor: 5.000

9.  Requirement of protein kinase D1 for pathological cardiac remodeling.

Authors:  Jens Fielitz; Mi-Sung Kim; John M Shelton; Xiaoxia Qi; Joseph A Hill; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-14       Impact factor: 11.205

10.  Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging.

Authors:  Brian G Reid; Matthew S Stratton; Samantha Bowers; Maria A Cavasin; Kimberley M Demos-Davies; Isidro Susano; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2016-04-27       Impact factor: 5.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.